Title: INX-315, an oral, potent and selective CDK2 inhibitor in patients with CDK4/6 inhibitor resistant ER+/HER2- breast cancer or CCNE1 amplified solid tumors: phase 1 monotherapy dose escalation ...

Q3 2024 Earnings Call Transcript October 30, 2024 Operator: Good morning. My name is Nadia, and I’ll be your conference operator today. At this time, I would like to welcome everyone to the Blueprint ...

Q3 2024 Earnings Call Transcript October 29, 2024 Incyte Corporation misses on earnings expectations. Reported EPS is $1.07 ...

Greetings, and welcome to the Incyte third-quarter financial results conference call and webcast. (Operator Instructions) As a reminder, this conference is being recorded. It's now my pleasure to turn ...

Pfizer's RSV rollback comes as the space has grown increasingly crowded. Besides marketed vaccines, Sanofi and AstraZeneca sell an antibody to protect infants, with Merck & Co. now eying a piece of ...

In September, Incyte presented late-breaking Phase 3 results for retifanlimab (Zynyz ®) and initial data from the Phase 1 ...

The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological ...

Savella (milnacipran) is another common SNRI and is used to manage fibromyalgia. Selective serotonin reuptake inhibitors (SSRIs) and SNRIs are both antidepressants but work differently. SSRIs work by ...

BioIVT, a global research partner and biospecimen solutions provider for drug and diagnostic development, today announced it will attend and sponsor the 8th Annual Biomarker & Precision Medicine U.S.

The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and hematological ...

The transcriptional regulation program is evaluating fadraciclib, a CDK2/9 inhibitor, and the anti-mitotic program plogosertib, a PLK1 inhibitor, in patients with both solid tumors and ...

ACE inhibitors are best known for treating high blood pressure. They work by targeting the hormone angiotensin II. Angiotensin-converting enzymes (ACE) inhibitors help blood vessels to relax and open.